Overview

Latent Tuberculosis in Type 2 Diabetes

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-04-18
Target enrollment:
Participant gender:
Summary
The patients with poorly controlled DM underwent LTBI screening by using QuantiFERON (QFT). QFT-positivity predictors were evaluated. The patients with LTBI received tuberculosis preventive therapy, 9 months of daily isoniazid (9H) or 3 months of weekly rifapentine plus isoniazid (3HP), administered by pulmonologists. The completion rates and inflammatory markers were also investigated.
Phase:
PHASE4
Details
Lead Sponsor:
Taichung Veterans General Hospital
Treatments:
Isoniazid
rifapentine